Vivani Medical Inc
VANI1.390USD
+0.060+4.51%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
82.35MCap. mercado
PérdidaP/E TTM
Más Datos de Vivani Medical Inc Compañía
Vivani Medical, Inc. is a biopharmaceutical company developing novel, ultra-long-acting drug implants. Leveraging its NanoPortal platform, the Company develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Its lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Its pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. NPM-119 refers to its Type II diabetes development program. OKV-119 is an exenatide implant that is under development for metabolic diseases in cats, including for the treatment of obesity and diabetes. Its segments include Biopharm Division and Neurostimulation Division.
Información de la empresa
Símbolo de cotizaciónVANI
Nombre de la empresaVivani Medical Inc
Fecha de salida a bolsaDec 05, 2014
Director ejecutivoDr. Adam Mendelsohn, Ph.D.
Número de empleados42
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 05
Dirección1350 S. Loop Road
CiudadALAMEDA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94502
Teléfono14155068462
Sitio Webhttps://vivani.com/
Símbolo de cotizaciónVANI
Fecha de salida a bolsaDec 05, 2014
Director ejecutivoDr. Adam Mendelsohn, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Adam Mendelsohn, Ph.D.
Dr. Adam Mendelsohn, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
3.75M
+1.58%
Mr. Aaron Mendelsohn
Mr. Aaron Mendelsohn
Independent Director
Independent Director
1.09M
--
Mr. Truc Le
Mr. Truc Le
Chief Operating Officer
Chief Operating Officer
46.66K
--
Mr. Donald (Don) Dwyer
Mr. Donald (Don) Dwyer
Corporate Secretary, Chief Business Officer
Corporate Secretary, Chief Business Officer
25.67K
+18.46%
Mr. Anthony Baldor
Mr. Anthony Baldor
Chief Financial Officer
Chief Financial Officer
--
--
Jami Taylor
Jami Taylor
Investor Relations Advisor
Investor Relations Advisor
--
--
Dr. Dean Baker, Ph.D.
Dr. Dean Baker, Ph.D.
Independent Director
Independent Director
--
--
Mr. Gregg G. Williams
Mr. Gregg G. Williams
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Daniel Mark (Dan) Bradbury
Mr. Daniel Mark (Dan) Bradbury
Independent Director
Independent Director
--
--
Ms. Alexandra Larson
Ms. Alexandra Larson
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Adam Mendelsohn, Ph.D.
Dr. Adam Mendelsohn, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
3.75M
+1.58%
Mr. Aaron Mendelsohn
Mr. Aaron Mendelsohn
Independent Director
Independent Director
1.09M
--
Mr. Truc Le
Mr. Truc Le
Chief Operating Officer
Chief Operating Officer
46.66K
--
Mr. Donald (Don) Dwyer
Mr. Donald (Don) Dwyer
Corporate Secretary, Chief Business Officer
Corporate Secretary, Chief Business Officer
25.67K
+18.46%
Mr. Anthony Baldor
Mr. Anthony Baldor
Chief Financial Officer
Chief Financial Officer
--
--
Jami Taylor
Jami Taylor
Investor Relations Advisor
Investor Relations Advisor
--
--
Desglose de ingresos
FY2019
FY2018
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
2.20M
0.00%
Italy
642.04K
0.00%
China
337.90K
0.00%
France
0.00
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Williams (Gregg)
30.87%
Bolck (Joachim Eberhard)
9.45%
Mendelsohn (Adam)
6.34%
Mendelsohn (Aaron)
1.83%
Tanager Wealth Management LLP
1.72%
Other
49.79%
Accionistas
Accionistas
Proporción
Williams (Gregg)
30.87%
Bolck (Joachim Eberhard)
9.45%
Mendelsohn (Adam)
6.34%
Mendelsohn (Aaron)
1.83%
Tanager Wealth Management LLP
1.72%
Other
49.79%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
49.03%
Investment Advisor
4.84%
Investment Advisor/Hedge Fund
2.56%
Hedge Fund
0.28%
Other
43.29%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
69
33.60M
56.72%
-556.17K
2025Q1
72
33.70M
56.88%
-726.81K
2024Q4
67
33.96M
57.33%
+2.68M
2024Q3
70
30.79M
54.55%
-493.25K
2024Q2
72
30.73M
54.46%
-999.37K
2024Q1
71
31.19M
60.37%
+7.51M
2023Q4
76
28.47M
55.90%
+4.85M
2023Q3
88
28.13M
55.24%
+3.68M
2023Q2
94
27.99M
55.13%
+4.81M
2023Q1
98
20.48M
40.40%
+6.26M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Williams (Gregg)
18.29M
30.87%
+105.15K
+0.58%
Apr 22, 2025
Bolck (Joachim Eberhard)
5.60M
9.45%
--
--
Mar 31, 2025
Mendelsohn (Adam)
3.75M
6.34%
+58.33K
+1.58%
Mar 31, 2025
Mendelsohn (Aaron)
1.09M
1.83%
--
--
Mar 31, 2025
Tanager Wealth Management LLP
1.22M
2.07%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
967.40K
1.63%
--
--
Mar 31, 2025
Sabby Management, LLC
851.61K
1.44%
-459.83K
-35.06%
Mar 31, 2025
Geode Capital Management, L.L.C.
360.53K
0.61%
+13.37K
+3.85%
Mar 31, 2025
Commonwealth Financial Network
330.53K
0.56%
--
--
Mar 31, 2025
Baker (Wilford Dean)
197.48K
0.33%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0.01%
iShares Micro-Cap ETF
Proporción0.01%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Fecha
Tipo
Relación
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
Aug 18, 2022
Merger
3<1
